Teleologically, this anomaly may contribute to tumor development analogous to what has been suggested for CLTC fusions with ALK in inflammatory myofibroblastic tumors and anaplastic large-cell lymphomas [10], and with TFE3 in renal cell carcinomas [11], [12]. The gene discussed is ALK; the disease is hereditary clear cell renal cell carcinoma.